On the Pulse of Progress: Applying Ovarian Cancer Advances Across the Pharmacy Spectrum

Program Description

Though ovarian cancer accounts for about 1% of new cancer diagnoses in US women, it remains one of the leading causes of gynecologic cancer death. Many patients continue to present with advanced disease and face high rates of recurrence, underscoring persistent challenges in early detection, durable disease control, and long-term survivorship despite meaningful therapeutic progress. In this context, oncology pharmacists may be increasingly involved in navigating complex frontline and maintenance strategies, managing platinum-sensitive and platinum-resistant relapse, and balancing efficacy, toxicity, cost, and access in routine practice. This program leverages the latest data from the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer to provide a focused review of selected abstracts in advanced ovarian cancer. Through multidisciplinary panel discussions led by oncology pharmacy experts, participants will explore evolving first-line and maintenance therapeutics, novel approaches in recurrent platinum-sensitive and platinum-resistant disease, and the operational and payer considerations that shape real-world implementation. By integrating clinical evidence with formulary, workflow, and access perspectives, this program equips oncology pharmacists to critically appraise new data, guide treatment and sequencing decisions, and lead efforts to ensure that innovations presented at SGO translate into meaningful improvements in patient care across both academic and community oncology settings.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 14, 2026
Expiration date: May 14, 2027
Learner level: Advanced
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore recent clinical updates on novel and emerging pharmacotherapeutic approaches for the management of advanced ovarian cancer presented at the 2026 SGO Annual Meeting on Women’s Cancer
• Examine how emerging clinical evidence in advanced ovarian cancer impacts oncology pharmacy practice, including both clinical decision-making and operational workflows
• Apply clinical insights alongside operational considerations and payer-related factors to guide the use of novel pharmacotherapeutic strategies for the individualized care of patients with advanced ovarian cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15CEU) under the ACPE universal activity number 0290-0000-26-126-H01-P The activity is available for CE credit through May 14, 2027

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Jennifer MacDonald, PharmD, BCOP , has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Verastem (advisory board)

Grant/research Support: GlaxoSmithKline, Verastem

Speakers Bureau: Dostarlimab, Niraparib

Abby Kim, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Shareholder: Prime Therapeutics

Mika R. K. Knable, PharmD, BCOP, DPLA has no relevant financial relationships with ineligible companies to disclose

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms